Kim, Jung-Min
Yang, Yeon-Suk
Xie, Jun
Lee, Oksun
Kim, JiHea
Hong, Jaehyoung
Boldyreff, Brigitte
Filhol, Odile http://orcid.org/0000-0003-1964-7958
Chun, Hyonho
Greenblatt, Matthew B.
Gao, Guangping http://orcid.org/0000-0003-0097-9012
Shim, Jae-Hyuck http://orcid.org/0000-0002-4947-3293
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR068983)
Article History
Received: 10 April 2021
Revised: 31 January 2022
Accepted: 2 February 2022
First Online: 15 February 2022
Competing interests
: JHS is a scientific co-founder of the AAVAA Therapeutics and holds equity in this company. GG is a scientific co-founder of AAVAA Therapeutics, Voyager Therapeutics, and Aspa Therapeutics and holds equity in these companies. GG is an inventor on patents with potential royalties licensed to Voyager Therapeutics, Aspa Therapeutics Inc., and other biopharmaceutical companies. Other authors declare no competing interests.
: All animals were used in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were handled according to protocols approved by the University of Massachusetts Medical School on animal care (IACUC).